QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.106.111559v1 319/3/1376    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Honore, P. Articles by Jarvis, M. F. Search for Related Content PubMed PubMed Citation Articles by Honore, P. Articles by Jarvis, M. F. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CALCIUM COMPOUNDS CALCIUM, ELEMENTAL VINCRISTINE Medline Plus Health Information Pain Peripheral Nerve Disorders

NEUROPHARMACOLOGY

A-740003 [N-(1-{[(Cyanoimino)(5-quinolinylamino) methyl]amino}-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide], a Novel and Selective P2X₇ Receptor Antagonist, Dose-Dependently Reduces Neuropathic Pain in the Rat

Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois

ATP-sensitive P2X₇ receptors are localized on cells of immunological origin including glial cells in the central nervous system. Activation of P2X₇ receptors leads to rapid changes in intracellular calcium concentrations, release of the proinflammatory cytokine interleukin-1 (IL-1), and following prolonged agonist exposure, cytolytic plasma membrane pore formation. P2X₇ knockout mice show reduced inflammation as well as decreased nociceptive sensitivity following peripheral nerve injury. A-740003 (N-(1-{[(cyanoimino)(5-quinolinylamino) methyl] amino}-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide) is a novel competitive antagonist of P2X₇ receptors (IC₅₀ values = 40 nM for human and 18 nM for rat) as measured by agonist-stimulated changes in intracellular calcium concentrations. A-740003 showed weak or no activity (IC₅₀ > 10 µM) at other P2 receptors and an array of other neurotransmitter and peptide receptors, ion channels, reuptake sites, and enzymes. A-740003 potently blocked agonist-evoked IL-1 release (IC₅₀ = 156 nM) and pore formation (IC₅₀ = 92 nM) in differentiated human THP-1 cells. Systemic administration of A-740003 produced dose-dependent antinociception in a spinal nerve ligation model (ED₅₀ = 19 mg/kg i.p.) in the rat. A-740003 also attenuated tactile allodynia in two other models of neuropathic pain, chronic constriction injury of the sciatic nerve and vincristine-induced neuropathy. In addition, A-740003 effectively reduced thermal hyperalgesia observed following intraplantar administration of carrageenan or complete Freund's adjuvant (ED₅₀ = 38–54 mg/kg i.p.). A-740003 was ineffective in attenuating acute thermal nociception in normal rats and did not alter motor performance at analgesic doses. These data demonstrate that selective blockade of P2X₇ receptors in vivo produces significant antinociception in animal models of neuropathic and inflammatory pain.

Address correspondence to: Dr. Michael F. Jarvis, Abbott Laboratories, R4PM, AP9A/311, 100 Abbott Park Road, Abbott Park, IL 60064. E-mail: michael.jarvis{at}abbott.com

This article has been cited by other articles:

				L. Nobbio, L. Sturla, F. Fiorese, C. Usai, G. Basile, I. Moreschi, F. Benvenuto, E. Zocchi, A. De Flora, A. Schenone, et al. P2X7-mediated Increased Intracellular Calcium Causes Functional Derangement in Schwann Cells from Rats with CMT1A Neuropathy J. Biol. Chem., August 21, 2009; 284(34): 23146 - 23158. [Abstract] [Full Text] [PDF]

				D. C. Broom, D. J. Matson, E. Bradshaw, M. E. Buck, R. Meade, S. Coombs, M. Matchett, K. K. Ford, W. Yu, J. Yuan, et al. Characterization of N-(Adamantan-1-ylmethyl)-5-[(3R-aminopyrrolidin-1-yl)methyl]-2-chloro-benzamide, a P2X7 Antagonist in Animal Models of Pain and Inflammation J. Pharmacol. Exp. Ther., December 1, 2008; 327(3): 620 - 633. [Abstract] [Full Text] [PDF]

				D. Donnelly-Roberts, S. McGaraughty, C.-C. Shieh, P. Honore, and M. F. Jarvis Painful Purinergic Receptors J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 409 - 415. [Abstract] [Full Text] [PDF]

				G. R. Dubyak Go It Alone No More P2X7 Joins the Society of Heteromeric ATP-Gated Receptor Channels Mol. Pharmacol., December 1, 2007; 72(6): 1402 - 1405. [Abstract] [Full Text] [PDF]

				L. Stokes and A. Surprenant Purinergic P2Y2 Receptors Induce Increased MCP-1/CCL2 Synthesis and Release from Rat Alveolar and Peritoneal Macrophages J. Immunol., November 1, 2007; 179(9): 6016 - 6023. [Abstract] [Full Text] [PDF]

				C. K. Donawho, Y. Luo, Y. Luo, T. D. Penning, J. L. Bauch, J. J. Bouska, V. D. Bontcheva-Diaz, B. F. Cox, T. L. DeWeese, L. E. Dillehay, et al. ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models Clin. Cancer Res., May 1, 2007; 13(9): 2728 - 2737. [Abstract] [Full Text] [PDF]